Drug intelligence / Profile preview

imprime PGG + bevacizumab + carboplatin + paclitaxel

Development stage: Unknown
Lead developer: HiberCell
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

A combination therapy consisting of Imprime PGG (a yeast-derived β-1,3/1,6 glucan pathogen-associated molecular pattern), bevacizumab (an anti-angiogenic monoclonal antibody targeting VEGF), and standard chemotherapy agents carboplatin and paclitaxel. This regimen aims to enhance anti-tumor immune responses by activating innate immune cells through Imprime PGG while simultaneously targeting tumor vasculature with bevacizumab and directly killing cancer cells with chemotherapy.

Targets

CLEC7A (Dectin-1)TUBB (Tubulin (alpha and beta subunits))VEGFA (Vascular endothelial growth factor A)DNA

Beyond the preview

Go deeper on imprime PGG + bevacizumab + carboplatin + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on imprime PGG + bevacizumab + carboplatin + paclitaxel.

Explore the full profile